Breakthrough in Fertility Treatment for Women with Premature Ovarian Insufficiency

A recent study conducted by researchers at the University of Hong Kong (HKU) has identified the potential of finerenone, a drug typically used for treating type 2 diabetes-related chronic kidney disease, to restore fertility in women suffering from premature ovarian insufficiency (POI). This condition affects approximately 1-3% of women of childbearing age globally and is characterized by a lack of ovarian follicular development, making conception difficult. The research indicates that finerenone can awaken dormant small follicles, promoting their development into mature eggs and viable embryos.

HKUMed, HKU Shenzhen Unveil POI Fertility BreakthroughSouth China Morning Post

Traditionally, treatments for POI have focused on stimulating follicles directly. However, the HKU study marks a significant shift towards enhancing the ovarian microenvironment, which is crucial for follicle growth. Professor Liu Kui, who led the research, emphasized that the study is pioneering in its approach to target the underlying conditions that inhibit follicular development, particularly ovarian fibrosis, which is characterized by excessive collagen deposition. This fibrosis not only affects older women but can also occur in younger patients, contributing to infertility.

HKUMed, HKU Shenzhen Unveil POI Fertility Breakthrough

The research team conducted a clinical trial at the University of Hong Kong-Shenzhen Hospital (HKU-SZH), where 14 women diagnosed with POI received pulsed oral therapy with finerenone, combined with personalized ovarian stimulation regimens over seven months. Preliminary results showed that eight participants developed antral follicles, with about half producing mature eggs. Notably, three participants successfully developed usable embryos, while others opted to freeze their oocytes. These findings suggest that finerenone could provide a viable treatment alternative with fewer side effects compared to traditional methods.

HKUMed, HKU Shenzhen Unveil POI Fertility Breakthrough

The study's implications extend beyond finerenone, as it also highlighted the potential of other FDA-approved antifibrotic drugs, such as Nintedanib and Ruxolitinib, to promote follicular development. This suggests that targeting the ovarian microenvironment may become a broader strategy in treating infertility. The research team plans to conduct larger-scale studies to further validate these findings and explore the clinical applications of this innovative treatment framework.

HKUMed, HKU Shenzhen Unveil POI Fertility Breakthrough

While the study presents promising results, some experts caution that further research is necessary to fully understand the long-term effects and efficacy of finerenone in diverse populations. Critics argue that the small sample size of the clinical trial may limit the generalizability of the findings.

HKUMed, HKU Shenzhen Unveil POI Fertility Breakthrough

Professor Ernest Ng Hung-yu, a clinical professor involved in the research, described the findings as a "paradigm shift" in treating POI, moving away from merely waiting for natural follicular development to actively improving the ovarian environment. He stated, "This is quite a breakthrough because the current treatment for patients who have premature ovarian insufficiency is to just wait."

South China Morning Post

• “The key is finding a way to awaken them and help them develop into usable antral follicles.” — Professor Liu Kui, HKUMed

HKUMed, HKU Shenzhen Unveil POI Fertility Breakthrough

• “Professor Ernest Ng Hung-yu, Clinical Professor in the Department of Obstetrics and Gynaecology at the School of Clinical Medicine, HKUMed, explained, 'Patients with POI often experience fibrosis, characterised by an excessive deposition of collagen in the ovarian microenvironment, which severely limits follicle growth and ultimately leads to infertility.” — Professor Ernest Ng Hung-yu, HKUMed

HKUMed, HKU Shenzhen Unveil POI Fertility Breakthrough

• “Professor Liu Kui stated, 'In the past, treatments for POI-related infertility focused mainly on directly stimulating the follicles, but the overall efficacy was limited.” — Professor Liu Kui, HKUMed

HKUMed, HKU Shenzhen Unveil POI Fertility Breakthrough

This research represents a significant advancement in the treatment of infertility related to POI, with the potential to change the lives of many women seeking to conceive.

HKUMed, HKU Shenzhen Unveil POI Fertility Breakthrough